[go: up one dir, main page]

NO20054085L - Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments - Google Patents

Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments

Info

Publication number
NO20054085L
NO20054085L NO20054085A NO20054085A NO20054085L NO 20054085 L NO20054085 L NO 20054085L NO 20054085 A NO20054085 A NO 20054085A NO 20054085 A NO20054085 A NO 20054085A NO 20054085 L NO20054085 L NO 20054085L
Authority
NO
Norway
Prior art keywords
pyrimidine
preparation
medicaments
methods
dione derivatives
Prior art date
Application number
NO20054085A
Other languages
Norwegian (no)
Inventor
Matthias Gossel
Thomas Klabunde
Siegfried Stengelin
Stefanie Flohr
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10305885A external-priority patent/DE10305885A1/en
Priority claimed from DE10349672A external-priority patent/DE10349672A1/en
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20054085L publication Critical patent/NO20054085L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Foreliggende oppfinnelse angår substituerte heksahydropyrazino[l,2-a]pyrimidin-4,7-dionderivater I tillegg til fysiologisk kompatible salter og fysiologisk fimksjonelle derivater derav. Oppfinnelsen angår også forbindelser med formel (I) hvori radikalene har den angitte betydningen, fysiologisk kompatible salter derav og fremgangsmåte for fremstilling derav. Forbindelsene kan anvendes for eksempel som anorektiske midler.The present invention relates to substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives In addition to physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to compounds of formula (I) wherein the radicals have the indicated meaning, physiologically compatible salts thereof and process for their preparation. The compounds may be used, for example, as anorectic agents.

NO20054085A 2003-02-13 2005-09-02 Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments NO20054085L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10305885A DE10305885A1 (en) 2003-02-13 2003-02-13 New pyrazinopyrimidine or pyrazinoimidazole derivatives useful for weight reduction in mammals, for preventing or treating obesity, type II diabetes or metabolic syndrome and for treating sexual disorders
DE10349672A DE10349672A1 (en) 2003-10-24 2003-10-24 New pyrazinopyrimidine or pyrazinoimidazole derivatives useful for weight reduction in mammals, for preventing or treating obesity, type II diabetes or metabolic syndrome and for treating sexual disorders
PCT/EP2004/000769 WO2004072076A1 (en) 2003-02-13 2004-01-29 Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments

Publications (1)

Publication Number Publication Date
NO20054085L true NO20054085L (en) 2005-09-02

Family

ID=32870334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054085A NO20054085L (en) 2003-02-13 2005-09-02 Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments

Country Status (21)

Country Link
EP (1) EP1599480B1 (en)
JP (1) JP2006517550A (en)
KR (1) KR20050111588A (en)
AR (1) AR043155A1 (en)
AT (1) ATE472548T1 (en)
AU (1) AU2004212042A1 (en)
BR (1) BRPI0407507A (en)
CA (1) CA2515735A1 (en)
CO (1) CO5690597A2 (en)
DE (1) DE502004011328D1 (en)
HR (1) HRP20050712A2 (en)
MA (1) MA27654A1 (en)
MX (1) MXPA05007516A (en)
MY (1) MY135902A (en)
NO (1) NO20054085L (en)
PE (1) PE20050192A1 (en)
PL (1) PL377227A1 (en)
RS (1) RS20050564A (en)
RU (1) RU2005128497A (en)
TW (1) TW200508235A (en)
WO (1) WO2004072076A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
DE502004007000D1 (en) * 2003-02-13 2008-06-12 Sanofi Aventis Deutschland NITROGEN SUBSTITUTED HEXAHYDRO-PYRAZINO 1,2-A PYRIMIDINE-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS
DE102004042441A1 (en) * 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Amino acid substituted hexahydro-pyrazino (1,2-a) pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
JP5536336B2 (en) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション Methods for the treatment of α-helix analogs and cancer stem cells
WO2007056513A1 (en) * 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
RU2009108280A (en) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PL2114933T3 (en) 2007-01-04 2012-02-29 Prosidion Ltd Piperidine gpcr agonists
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
AR064736A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (en) 2009-08-26 2012-06-13 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use.
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2024217497A1 (en) * 2023-04-21 2024-10-24 The University Of Hong Kong Novel small molecule agonists of insulin receptor (insr) as anti-diabetes drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6251902B1 (en) * 1997-06-25 2001-06-26 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US6294525B1 (en) * 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
DE502004007000D1 (en) * 2003-02-13 2008-06-12 Sanofi Aventis Deutschland NITROGEN SUBSTITUTED HEXAHYDRO-PYRAZINO 1,2-A PYRIMIDINE-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS

Also Published As

Publication number Publication date
BRPI0407507A (en) 2006-02-14
EP1599480A1 (en) 2005-11-30
ATE472548T1 (en) 2010-07-15
MXPA05007516A (en) 2006-01-27
JP2006517550A (en) 2006-07-27
KR20050111588A (en) 2005-11-25
DE502004011328D1 (en) 2010-08-12
CA2515735A1 (en) 2004-08-26
PL377227A1 (en) 2006-01-23
MA27654A1 (en) 2005-12-01
AU2004212042A1 (en) 2004-08-26
HRP20050712A2 (en) 2006-09-30
AR043155A1 (en) 2005-07-20
TW200508235A (en) 2005-03-01
RS20050564A (en) 2007-09-21
RU2005128497A (en) 2006-01-27
WO2004072076A1 (en) 2004-08-26
MY135902A (en) 2008-07-31
CO5690597A2 (en) 2006-10-31
EP1599480B1 (en) 2010-06-30
PE20050192A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
NO20054085L (en) Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments
NO20054208L (en) Nitrogen-substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments
TNSN05194A1 (en) Substituted n-arylheterocycles, method for production and use thereof as medicaments
MX337817B (en) PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES.
TW200606162A (en) Pyrazolopyridine derivatives
MX2010006748A (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS.
NO20054905L (en) 2-acylamino-4-phenylthiazole derivatives, methods for their preparation and use of the same as in therapeutics
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
BRPI0510560A (en) substituted pyrido [2,3-d] pyrimidin-7-ones and their derivatives as therapeutic agents
NO20055649L (en) Substituted dihydroquinazoline with antivial properties
NO20056032L (en) Novel pyridopyrazines and their use as kinase modulators
CY1109366T1 (en) Substituted Compounds 1,4,8-Triazazepiro [4.5] Decan-2-One
PT1869038E (en) Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs
NO20072089L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
PL1730147T3 (en) Substituted 1,4,8-triazaspiro[4,5]decan-2-on compounds for use in the treatment of obesity
UA83821C2 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
BRPI0513287A (en) pyrido pyrimidine derivatives, their preparation, their application in therapeutic
NO20053809L (en) Diarylmethylindenepiperidine derivatives, process for their preparation, and use thereof
TW200510399A (en) 1, 3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
NO20053805L (en) Diarylmethylindenepiperidine derivatives, processes for their preparation, and use thereof
NO20053876L (en) Carbonylamino-substituted acylphenylurea derivatives, process for their preparation and use thereof
EA200600318A1 (en) DERIVATIVES 3-NITROPYRAZOLO [1,5-a] PYRIMIDINES, METHOD OF THEIR PRODUCTION, MEDICATION (OPTIONS) AND METHOD OF TREATMENT OR PREVENTION OF DISEASE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application